• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis.

作者信息

Dhote Théo, Martin Clémence, Regard Lucile, Pesenti Lucie, Kanaan Reem, Carlier Nicolas, Honoré Isabelle, Da Silva Jennifer, Witko-Sarsat Véronique, Burgel Pierre-Régis

机构信息

Université de Paris Cité, Institut Cochin, INSERM U1016, CNRS-UMR-8104, Paris, France.

Department of Respiratory Medicine, National Reference Cystic Fibrosis Center, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.

出版信息

Eur Respir J. 2023 Jan 6;61(1). doi: 10.1183/13993003.02096-2022. Print 2023 Jan.

DOI:10.1183/13993003.02096-2022
PMID:36455960
Abstract
摘要

相似文献

1
Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis.在晚期囊性纤维化患者中，接受艾列卡福妥-替扎卡福妥-依伐卡福妥治疗12个月后循环中性粒细胞计数恢复正常。
Eur Respir J. 2023 Jan 6;61(1). doi: 10.1183/13993003.02096-2022. Print 2023 Jan.
2
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
3
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
4
Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes.囊性纤维化-门控和-残留功能基因型的三联疗法。
N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665.
5
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.依列卡福妥联合替扎卡福妥和依伐卡托对比替扎卡福妥联合依伐卡托治疗F508del-CFTR纯合子囊性纤维化患者的疗效和安全性：一项为期24周的多中心、随机、双盲、活性对照3b期试验
Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20.
6
Elexacaftor/Ivacaftor/Tezacaftor: First Approval.依伐卡托/埃乐卡福特/泰泽卡福特：首次批准。
Drugs. 2019 Dec;79(18):2001-2007. doi: 10.1007/s40265-019-01233-7.
7
Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.适合调节剂药物的患者：来自土耳其囊性纤维化登记处的数据。
Pediatr Pulmonol. 2020 Sep;55(9):2302-2306. doi: 10.1002/ppul.24854. Epub 2020 May 26.
8
Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.基于生理的药代动力学引导用于 COVID-19 治疗中接受 Elexacaftor-Tezacaftor-Ivacaftor 联合奈玛特韦-利托那韦治疗的囊性纤维化患者。
Clin Pharmacol Ther. 2022 Jun;111(6):1324-1333. doi: 10.1002/cpt.2585. Epub 2022 Apr 6.
9
Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis.一名患有囊性纤维化的青春期女性过量服用依列卡福妥-替扎卡福妥-依伐卡福。
Pediatr Pulmonol. 2022 Dec;57(12):3174-3176. doi: 10.1002/ppul.26116. Epub 2022 Aug 24.
10
Challenged Urine Bicarbonate Excretion as a Measure of Cystic Fibrosis Transmembrane Conductance Regulator Function in Cystic Fibrosis.挑战尿碳酸氢盐排泄作为囊性纤维化跨膜电导调节剂功能的衡量标准在囊性纤维化中的应用。
Ann Intern Med. 2022 Nov;175(11):1543-1551. doi: 10.7326/M22-1741. Epub 2022 Nov 1.

引用本文的文献

1
Elexacaftor/tezacaftor/ivacaftor (ETI) therapy modifies the expression of interferon beta and inflammatory genes in the airways of adult patients with cystic fibrosis: a pilot study.依列卡福妥/替扎卡福妥/依伐卡托（ETI）疗法改变成年囊性纤维化患者气道中干扰素β和炎症基因的表达：一项试点研究。
Mol Cell Biochem. 2025 Jun 25. doi: 10.1007/s11010-025-05331-x.
2
The Role of Triple CFTR Modulator Therapy in Reducing Systemic Inflammation in Cystic Fibrosis.三联CFTR调节剂疗法在减轻囊性纤维化全身炎症中的作用
Lung. 2025 Mar 28;203(1):55. doi: 10.1007/s00408-025-00806-6.
3
Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study.
依列卡福妥/替扎卡福妥/依伐卡托与囊性纤维化儿童及青少年的炎症：一项回顾性双中心队列研究
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251314706. doi: 10.1177/17534666251314706.
4
in chronic lung disease: untangling the dysregulated host immune response.在慢性肺部疾病中：理清失调的宿主免疫反应。
Front Immunol. 2024 Jun 28;15:1405376. doi: 10.3389/fimmu.2024.1405376. eCollection 2024.
5
Plasma levels of chemokines decrease during elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis.在接受依列卡福妥/替扎卡福妥/依伐卡福妥治疗的成年囊性纤维化患者中，趋化因子的血浆水平会降低。
Heliyon. 2023 Dec 12;10(1):e23428. doi: 10.1016/j.heliyon.2023.e23428. eCollection 2024 Jan 15.
6
Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies.囊性纤维化肺部炎症基因及其与囊性纤维化跨膜电导调节剂治疗的相关性。
Genes (Basel). 2023 Oct 20;14(10):1966. doi: 10.3390/genes14101966.
7
Multimodal analysis of granulocytes, monocytes, and platelets in patients with cystic fibrosis before and after Elexacaftor-Tezacaftor-Ivacaftor treatment.囊性纤维化患者在接受 Elexacaftor-Tezacaftor-Ivacaftor 治疗前后的粒细胞、单核细胞和血小板的多模态分析。
Front Immunol. 2023 Jun 29;14:1180282. doi: 10.3389/fimmu.2023.1180282. eCollection 2023.
8
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.CFTR调节剂依列卡福-替扎卡福-依伐卡福的批准后研究。
Front Pharmacol. 2023 Mar 21;14:1158207. doi: 10.3389/fphar.2023.1158207. eCollection 2023.
9
Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis.依列卡福妥-替扎卡福妥-依伐卡托：用于囊性纤维化的改变人生的三联组合CFTR调节剂药物。
Pharmaceuticals (Basel). 2023 Mar 8;16(3):410. doi: 10.3390/ph16030410.